Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.71 |
| ▸ | HPGD | P15428 | 3/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | STAT3 | P40763 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31283651 | 1.00 | ALDH1A1 (0.71) | ALDH1A1HPGDHSD17B10KDM4EPOLB | |
| SCHEMBL63778 | 0.86 | ALDH1A1 (0.73) | ALDH1A1HPGDHSD17B10KDM4EPOLB | |
| SCHEMBL25022813 | 0.85 | UBE2T (0.57) | ALDH1A1HPGDHSD17B10KDM4EPOLB | |
| SCHEMBL23929985 | 0.85 | UBE2T (0.61) | ALDH1A1HPGDHSD17B10KDM4EPOLB | |
| SCHEMBL30175332 | 0.85 | UBE2T (0.61) | ALDH1A1HPGDHSD17B10KDM4EPOLB | |
| SCHEMBL23655010 | 0.84 | ALDH1A1 (0.62) | ALDH1A1HPGDHSD17B10KDM4EPOLB | |
| SCHEMBL357927 | 0.84 | ALDH1A1 (0.71) | ALDH1A1HPGDHSD17B10KDM4EPOLB | |
| SCHEMBL2974981 | 0.84 | ALDH1A1 (0.71) | ALDH1A1HPGDHSD17B10KDM4EPOLB | |
| Hydrochloric Acid SCHEMBL19119306 | 0.84 | ALDH1A1 (0.71) | ALDH1A1HPGDHSD17B10KDM4EPOLB | |
| SCHEMBL19160257 | 0.84 | ALDH1A1 (0.71) | ALDH1A1HPGDHSD17B10KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856736-B1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2026-05-06 | — | — | EP | disclosed |
| US-12202816-B2 | Compounds as NADPH oxidase inhibitors | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2025-01-21 | — | — | US | disclosed |
| US-20220033379-A1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2022-02-03 | — | — | US | disclosed |
| US-20220033379-A1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2022-02-03 | — | — | US | disclosed |
| US-11034725-B2 | Compositions and methods for treating cardiovascular disease | GENENTECH, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| CN-112930346-A | Novel compounds as NADPH oxidase inhibitors | 金其尤泰克斯瑞士股份有限公司 | 2021-06-08 | — | — | CN | disclosed |
| US-20200283478-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | GENENTECH, INC. (US) | 2020-09-10 | — | — | US | disclosed |
| EP-3628669-A1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | GenKyoTex Suisse SA (CH) | 2020-04-01 | — | — | EP | disclosed |
| EP-3628669-A1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | GenKyoTex Suisse SA (CH) | 2020-04-01 | — | — | EP | disclosed |
| EP-1921077-B1 | AGENT FOR TREATING AND/OR PREVENTING SLEEP DISORDER | KYOWA HAKKO KIRIN CO LTD (JP) | 2017-07-26 | — | — | EP | disclosed |
| WO-2007067836-A2 | SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-14 | — | — | WO | disclosed |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20050245518-A1 | Antiproliferative agents | METHYLGENE, INC. | 2005-11-03 | — | — | US | disclosed |
| EP-1196407-A1 | N-IMIDAZOLYLMETHYL CARBOXAMIDES AS NITRIC OXIDE PRODUCTION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001002387-A1 | N-IMIDAZOLYLMETHYL CARBOXAMIDES AS NITRIC OXIDE PRODUCTION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-01-11 | — | — | WO | disclosed |
| CN-1252070-A | 5,7-disubstituted 4-aminopyrido [2,3,-d] pyrimidine compounds and their use as adenosine kinase inhibitors | ABBOTT LAB (US) | 2000-05-03 | — | — | CN | disclosed |
| WO-2000023444-A1 | 5,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-04-27 | — | — | WO | disclosed |
| EP-0989986-A1 | 5,7-DISUBSTITUTED 4-AMINOPYRIDO 2,3-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS ADENOSINE KINASE INHIBITORS | Abbott Laboratories (US) | 2000-04-05 | — | — | EP | disclosed |
| WO-1998046605-A1 | 5,7-DISUBSTITUTED 4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS ADENOSINE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 1998-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283478-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | PCSK9, PCSK7, PCSK6 | ALDH1A1 4023/4885HPGD 2382/4885HSD17B10 315/4885 |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | ADORA2A, ADORA3, ADORA1 | ALDH1A1 2843/4885HPGD 3839/4885HSD17B10 3869/4885 |
| US-11034725-B2 | Compositions and methods for treating cardiovascular disease | PCSK9, PCSK7, PCSK6 | ALDH1A1 4023/4885HPGD 2382/4885HSD17B10 315/4885 |
| US-12202816-B2 | Compounds as NADPH oxidase inhibitors | CYBB, NOX1, NOX4 | ALDH1A1 285/4885HPGD 21/4885HSD17B10 338/4885 |
| US-20050245518-A1 | Antiproliferative agents | HDAC1, HDAC11, HDAC5 | ALDH1A1 758/4885HPGD 971/4885HSD17B10 824/4885 |
| US-20220033379-A1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | CYBB, NOX1, NOX4 | ALDH1A1 309/4885HPGD 25/4885HSD17B10 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.